Every 10-Q that ARTIVA BIOTHERAPEUTICS INC (ARTV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ARTV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARTV filings page.
Artiva Biotherapeutics, Inc. develops off-the-shelf allogeneic NK cell therapies for autoimmune diseases, led by AlloNK. For the quarter ended June 30, 2026, it reported a net loss of $25.0 million ($0.63 per share) and a six‑month net loss of $48.5 million.
Operating expenses increased as R&D reached $21.9 million in the quarter, driven largely by AlloNK. A May 2026 public offering of common stock and pre‑funded warrants generated $300.0 million in gross proceeds and $282.7 million net, lifting cash, cash equivalents and investments to $349.4 million and stockholders’ equity to $347.5 million.
Artiva reported encouraging AlloNK data in refractory rheumatoid arthritis, Sjögren’s disease and systemic sclerosis, with meaningful clinical responses and deep B‑cell depletion. The FDA granted Fast Track and RMAT designations for AlloNK in refractory RA and aligned on a single Phase 3 randomized trial of approximately 150 patients using ACR50 at six months as the primary endpoint. Management states existing capital should fund planned operations for at least one year, with additional financing required to complete development and potential commercialization.
Artiva Biotherapeutics reported a net loss of $23.5 million (basic and diluted loss of $0.95 per share) for the quarter ended March 31 2026, reflecting continued investment in its NK cell therapy pipeline.
Research and development expenses rose to $19.3 million, driven mainly by clinical work on lead candidate AlloNK, while general and administrative costs were stable at $5.1 million. Net cash used in operating activities was $21.0 million.
The company ended the quarter with $86.8 million in cash, cash equivalents and short-term investments and an accumulated deficit of $354.1 million. Management believes this cash runway funds planned operations into the second quarter of 2027 as Artiva advances AlloNK toward a planned Phase 3 trial in refractory rheumatoid arthritis.
Artiva Biotherapeutics (ARTV) reported Q3 2025 results marked by continued R&D investment and no product revenue. The company recorded a net loss of $21.5 million for the quarter and $63.1 million year‑to‑date. Q3 operating expenses were $22.9 million, driven by R&D of $17.6 million and G&A of $5.3 million. Net loss per share was $0.88 on 24.5 million weighted‑average shares.
Liquidity remained solid with $25.5 million in cash and cash equivalents and $97.5 million in short‑term investments, totaling $123.0 million as of September 30, 2025. The company used $62.0 million in cash for operating activities in the first nine months. Stockholders’ equity was $129.2 million, with total assets of $148.9 million. Management states existing cash, cash equivalents and investments will be sufficient to fund planned operations for at least one year from the issuance of these financial statements.
Artiva continues advancing NK cell programs, including AlloNK, under licensing and collaboration agreements with GC Cell. Shares outstanding were 24,544,904 as of October 31, 2025.